TTR Stabilizer Therapy
Definition
TTR stabilizer therapy refers to small molecules that bind to the T4 thyroid hormone-binding sites at the dimer–dimer interface of the transthyretin (TTR) tetramer, kinetically stabilizing it against dissociation into amyloidogenic monomers. By inhibiting the rate-limiting step of tetramer dissociation, stabilizers reduce the concentration of misfolded monomers available for amyloid fibril formation and deposition in the myocardium. Two agents — tafamidis and acoramidis — have completed Phase 3 trials in ATTR-CM with positive primary outcomes; both stabilize all TTR variants tested (wild-type and mutant).
Key Concepts
Molecular Mechanism
- TTR is a homotetrameric protein; pathological cascade: tetramer dissociation → monomer misfolding → amyloid fibril formation → myocardial deposition → restrictive cardiomyopathy
- The T4 thyroid hormone-binding pockets sit at the dimer–dimer interface; ligand binding shifts the equilibrium toward the tetrameric state (kinetic stabilization)
- T119M natural variant: a rare protective TTR missense variant that stabilizes the tetramer through unique intramolecular hydrogen bonding; T119M heterozygosity protects V30M compound heterozygotes from amyloidosis and may increase lifespan in the general population (sources/acoramidis-attrcm-attributecm-nejm-2024, rating: very high)
- Tafamidis binding mode: predominantly entropic (hydrophobic interactions); achieves partial stabilization
- Acoramidis binding mode: primarily enthalpic (hydrogen bonding mimicking T119M); achieves >90% stabilization across the dosing interval vs less complete stabilization with tafamidis (sources/acoramidis-attrcm-attributecm-nejm-2024, rating: very high)
- X-ray crystallography of acoramidis–TTR cocrystals confirmed binding at T4 sites with T119M-like hydrogen bonding pattern (sources/acoramidis-attrcm-attributecm-nejm-2024, rating: very high)
- Dose–response concept: in tafamidis long-term extension (median 58 months), higher TTR stabilization associated with better clinical outcomes, supporting the concept that more complete stabilization confers greater benefit (sources/acoramidis-attrcm-attributecm-nejm-2024, rating: very high)
Tafamidis (ATTR-ACT, NEJM 2018)
- First approved TTR stabilizer for ATTR-CM (FDA 2019: ATTRwt and ATTRv)
- ATTR-ACT (30 months): all-cause mortality HR 0.70; CV hospitalization HR 0.68; 6MWT decline less; KCCQ-OS decline less; 30-month survival 70.5% in combined tafamidis groups vs lower in placebo
- Tafamidis 80 mg OD (free acid equivalent of 61 mg) — active dose; lower dose (20 mg) less effective
- Binding is primarily entropic (hydrophobic); achieves partial stabilization (lower % than acoramidis)
- Referenced in sources/acoramidis-attrcm-attributecm-nejm-2024 as comparator context
Acoramidis (ATTRibute-CM, NEJM 2024)
- Second TTR stabilizer with Phase 3 evidence; BridgeBio Pharma; also called AG10
- Dose: 800 mg BID (hydrochloride salt)
- ATTRibute-CM (n=632; 90.3% ATTRwt; 30 months): (sources/acoramidis-attrcm-attributecm-nejm-2024, rating: very high)
- 4-step primary hierarchical (death/CV hosp/NT-proBNP/6MWT): win ratio 1.8 (95% CI 1.4–2.2; P<0.001)
- CV hospitalization: relative risk ratio 0.496 (P<0.001)
- NT-proBNP geometric mean factor change ratio: 0.529 at 30 months
- 6MWT: +39.6 m (P<0.001)
- KCCQ-OS: +9.94 points (P<0.001)
- Serum TTR: +7.01 mg/dL (P<0.001)
- 30-month survival: 80.7% vs 74.3%; Cox model violated proportional hazards; log-rank (sensitivity) NS; curves diverged at ~19 months
- SAEs: 54.6% vs 64.9% (fewer with acoramidis)
- Superiority over tafamidis in pre-clinical potency/affinity assays; no head-to-head clinical RCT
- FDA approval status: approved 2024 (US) as Attruby for ATTR-CM
Pharmacological Comparison
| Feature | Tafamidis | Acoramidis |
|---|---|---|
| Binding mode | Entropic (hydrophobic) | Enthalpic (hydrogen bonding; T119M mimicry) |
| % TTR stabilization | Partial | >90% across dosing interval |
| Dosing | 80 mg OD | 800 mg BID |
| Phase 3 trial | ATTR-ACT (NEJM 2018) | ATTRibute-CM (NEJM 2024) |
| Primary endpoint met | Yes (hierarchical) | Yes (win ratio 1.8) |
| 30-month survival (treated) | 70.5% | 80.7% |
| Mortality HR significance | Yes (HR 0.70) | No (Cox model violations; log-rank NS) |
| CV hosp reduction | HR 0.68 | RR 0.496 |
| Approved indications | ATTRwt + ATTRv ATTR-CM | ATTRwt + ATTRv ATTR-CM |
Serum TTR as Pharmacodynamic Marker
- In ATTR-CM, serum TTR is typically below normal or low-normal (TTR secreted from liver is incorporated into amyloid deposits)
- Acoramidis caused a sustained rise in serum TTR (+7.01 mg/dL at 30 months) — reflects reduced hepatic TTR incorporation into amyloid; serves as pharmacodynamic proof-of-mechanism (sources/acoramidis-attrcm-attributecm-nejm-2024, rating: very high)
- Serum TTR rise is a class effect of stabilizers (also observed with tafamidis)
Contradictions / Open Questions
- No head-to-head acoramidis vs tafamidis: ATTRibute-CM showed better pre-clinical potency/stabilization for acoramidis and numerically better survival at 30 months (80.7% vs tafamidis 70.5% in ATTR-ACT), but different trial populations, time periods, and NT-proBNP thresholds prohibit direct comparison. Whether acoramidis is clinically superior to tafamidis is unknown. (sources/acoramidis-attrcm-attributecm-nejm-2024)
- Delayed mortality benefit: Survival curves in ATTRibute-CM diverged only at ~19 months, identical to the pattern in ATTR-ACT for tafamidis. This delayed separation means early-stage or pre-clinical ATTR-CM patients are underrepresented in current trials, and the magnitude of benefit from initiating therapy before overt HF is not established. (sources/acoramidis-attrcm-attributecm-nejm-2024)
- More complete stabilization = better outcomes?: Tafamidis long-term extension data support a dose–response between stabilization level and mortality. Acoramidis achieves higher stabilization. However, no trial has directly tested whether replacing tafamidis with acoramidis improves outcomes in patients already on a stabilizer. (sources/acoramidis-attrcm-attributecm-nejm-2024)
- TTR stabilizers vs RNAi — complementary or competing?: Tafamidis (HR 0.70), acoramidis (trend), and vutrisiran (HR 0.65 through 42 months) each have Phase 3 trial data. Patisiran (APOLLO-B, 12 months) demonstrated preserved functional capacity but failed hard endpoints — trial too short. Whether combining a stabilizer with RNAi provides additive benefit, and the optimal sequence/monotherapy choice, has not been studied. (sources/vutrisiran-attrcm-heliosb-nejm-2025, sources/acoramidis-attrcm-attributecm-nejm-2024, sources/patisiran-attrcm-apollob-nejm-2023)
- Patisiran vs vutrisiran — trial duration or drug effect?: APOLLO-B (patisiran, 12 months) failed hard composite endpoints; HELIOS-B (vutrisiran, up to 42 months) demonstrated mortality benefit. Patisiran achieves higher TTR knockdown (87% vs 81%) yet showed no mortality signal. Impossible to distinguish whether this reflects trial duration, SC vs IV delivery compliance, or a pharmacological difference without a head-to-head adequately powered trial. (sources/patisiran-attrcm-apollob-nejm-2023)
- Protocol amendments in ATTRibute-CM: The primary endpoint evolved from 2-component to 4-component during the trial. Although changes were pre-registered and rationale documented, this introduces interpretive caution about the endpoint hierarchy weighting. (sources/acoramidis-attrcm-attributecm-nejm-2024)
Connections
- Related to entities/ATTR-Amyloidosis — disease entity for which this therapy class exists
- Related to entities/Vutrisiran — RNAi class; HELIOS-B 2025 mortality benefit in ATTR-CM
- Related to entities/Patisiran — first RNAi agent in ATTR-CM; APOLLO-B proof-of-concept; predecessor to vutrisiran
- Related to concepts/Cardiac-Amyloidosis-Imaging — imaging for diagnosis and monitoring